This retrospective study will leverage previous immune function monitoring results in conjunction with clinical case data at this medical center.
The primary aim of this study is to evaluate the efficacy and safety of PD(L)-1 antibody therapy for malignant tumors in real-world settings. Treatment outcomes will be assessed according to RECIST V1.1 and iRECIST criteria, with safety graded according to CTCAE V5.0 standards. The study aims to enroll 3000 adult cancer patients treated at this center and analyze their prognosis outcomes based on previous treatment.
Study Type
OBSERVATIONAL
Enrollment
3,000
Patients received PD-1 inhibitors mono- or combined therapy in real-world clinical practice
Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
Zhengzhou, Henan, China
RECRUITINGObjective response rate
The objective response rate at 6 months
Time frame: 6 months
Adverse events
Number of participants who experienced immune-related adverse events at 1 year according to CTCAE 5.0
Time frame: 1 year
Overall survival
The overall survival rate at 1 year
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.